Summary & Overview
CPT 0537U: Shield™ (Guardant) cfDNA Methylation Assay for Colorectal Cancer
CPT code 0537U designates Shield™, a proprietary Guardant Health laboratory test that uses next‑generation sequencing to evaluate cell‑free DNA methylation across over 2,500 genomic regions to detect signals associated with colorectal cancer. As a PLA code, 0537U is specific to a single manufacturer’s assay and is reportable only for that test. Nationally, such PLA codes matter because they identify unique diagnostic products with specific clinical roles in cancer detection and carry distinct coding and coverage considerations.
Key payers discussed include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a concise briefing on the clinical purpose and laboratory service model for Shield™, an outline of typical sites of service, and a summary of payer coverage context. The publication also covers benchmarks and policy updates relevant to proprietary laboratory assays, payer approaches to coverage for cell‑free DNA methylation testing, and clinical context for test interpretation and utilization.
The report is intended to inform billing and policy teams, laboratory operations, and clinical stakeholders about coding specifics, payer engagement considerations, and where to locate detailed coverage guidance for this unique, single‑manufacturer NGS methylation assay.
Billing Code Overview
CPT code 0537U is a Proprietary Laboratory Analyses (PLA) code that applies only to a single, manufacturer-specific test: Shield™ by Guardant Health Inc. The test analyzes cell–free DNA from a blood sample to detect methylation patterns across more than 2,500 genomic regions that are associated with colorectal cancer. Results are reported as either positive or negative.
Service type: Laboratory — cell‑free DNA methylation assay using next‑generation sequencing (NGS)
Typical site of service: Clinical laboratory or outpatient phlebotomy collection site, with blood draw performed in an ambulatory or outpatient setting and sequencing and analysis completed in the performing laboratory.
Clinical & Coding Specifications
Clinical Context
A 64-year-old average-risk patient presents to a primary care clinic for colorectal cancer screening but prefers a noninvasive option. The clinician counsels the patient on available screening modalities and orders Guardant Health’s Shield™ blood-based assay (0537U) as an alternative to stool-based tests or colonoscopy. A phlebotomy encounter is scheduled in an outpatient laboratory or hospital laboratory setting. Blood is drawn, labeled with required identifiers, and shipped under appropriate chain-of-custody conditions to the performing laboratory. The laboratory performs next-generation sequencing and targeted methylation analysis of cell-free DNA across >2500 genomic regions and returns a binary result: positive (suspicious for colorectal cancer) or negative. A positive result prompts referral to gastroenterology for diagnostic colonoscopy and tissue diagnosis. A negative result may lead to continued routine screening per guidelines and shared decision-making.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|
00 | No modifier | Standard reporting when no modifier applies |
26 | Professional component |